Evidence map›Paper›PMID 42489791›Full record

ArticleJournal of neuro-oncology2026

Extent of resection and survival in IDH-wildtype glioblastoma: interaction with MGMT status and chemoradiation.

Noah B Drewes, Lara Koutah, Rishi Jain, Jack Carnduff, Kayla Chin, Kristin R Delfino, Jeffrey W Cozzens, Bruce M Frankel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Noah B Drewes *Division of Neurosurgery, Department of Surgery, Southern Illinois University School of Medicine, 801 N. Rutledge St., PO Box 19620, Springfield, IL, 62702, USA. ndrewes45@siumed.edu.ORCID http://orcid.org/0009-0006-2636-0516
Lara Koutah *Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Rishi JainDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Jack CarnduffDivision of Neurosurgery, Department of Surgery, Southern Illinois University School of Medicine, 801 N. Rutledge St., PO Box 19620, Springfield, IL, 62702, USA.
Kayla ChinDivision of Neurosurgery, Department of Surgery, Southern Illinois University School of Medicine, 801 N. Rutledge St., PO Box 19620, Springfield, IL, 62702, USA.
Kristin R DelfinoCenter for Clinical Research, Southern Illinois University School of Medicine, Springfield, IL, USA.
Jeffrey W CozzensDivision of Neurosurgery, Department of Surgery, Southern Illinois University School of Medicine, 801 N. Rutledge St., PO Box 19620, Springfield, IL, 62702, USA.
Bruce M FrankelDivision of Neurosurgery, Department of Surgery, Southern Illinois University School of Medicine, 801 N. Rutledge St., PO Box 19620, Springfield, IL, 62702, USA.

Funding

Springfield Memorial Foundation 2018-31
6 · The paper itself

Abstract

purposeWhether gross total resection (GTR) remains associated with survival among MGMT-methylated IDH-wildtype glioblastoma patients receiving chemoradiation remains uncertain. We evaluated whether GTR versus less-than-GTR (< GTR) was associated with overall survival across MGMT promoter methylation and chemoradiation strata.

methodsWe retrospectively reviewed 261 patients undergoing biopsy or resection for newly diagnosed IDH-wildtype glioblastoma at a single institution from 2010 to 2024. Extent of resection was dichotomized as GTR versus < GTR, and chemoradiation was coded as receipt of postoperative radiation and temozolomide. Overall survival was assessed using Kaplan-Meier analysis and multivariable Cox models with prespecified EOR × MGMT × chemoradiation interaction testing, adjusted for age, KPS, tumor location, and mFI-5.

resultsGTR was associated with longer overall survival than < GTR in the overall cohort and within all four MGMT × chemoradiation strata. MGMT-methylated patients receiving chemoradiation had a median overall survival of 17.02 months after GTR versus 10.65 months after < GTR (log-rank p = 0.001), and the model-derived adjusted hazard ratio for < GTR versus GTR was 2.12 (95% CI 1.27-3.54; p = 0.004). The three-way EOR × MGMT × chemoradiation interaction was not significant (likelihood-ratio p = 0.309). In a 6-week sensitivity analysis, all survival associations remained, but EOR × chemoradiation was no longer significant.

conclusionGTR was associated with longer survival across all MGMT and chemoradiation-defined subgroups, including MGMT-methylated patients receiving chemoradiation. These findings are consistent with maximal safe resection when feasible but should be interpreted cautiously because of small subgroups as well as treatment-selection and immortal-time biases.

Indexed as

Brain NeoplasmsChemoradiotherapyDNA Modification MethylasesDNA Repair EnzymesGlioblastomaIsocitrate DehydrogenaseNeurosurgical ProceduresTumor Suppressor ProteinsAdultAgedDNA MethylationFemaleFollow-Up StudiesHumansMaleMiddle AgedDNA Modification MethylasesDNA Repair EnzymesIsocitrate DehydrogenaseMGMT protein, humanTumor Suppressor ProteinsChemoradiationExtent of resectionGlioblastomaIDH-wildtypeMGMT promoter methylationOverall survival

Identifiers

PMID42489791
PMCPMC13395848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.